

REMARKS

I. Claim status

Applicants have amended claims 1, 3, and 11 and added new claims 25-30. Claims 2, 4, 7-10, and 13-22 were previously cancelled. New claims 25-30 read on the elected invention. All amendments are without prejudice. Upon entry of this amendment, claims 1, 3, 5, 6, 11, 12, and 23-30 will be pending and under examination.

Support for the amendments can be found throughout the application, including paragraphs 12, 14, and 15 of the published application, U.S. Patent Application Publication No. 20060292129. These amendments are fully supported by the application, do not add new matter, and Applicants respectfully request their entry.

II. Rejections under 35 U.S.C. § 102(b) and 35 U.S.C. § 103(a)

Solely to facilitate prosecution, Applicants have amended claims 1, 3, and 11, from which all rejected claims depend, to clarify that the cell line recited in the claims “synthesizes and expresses [the recited antigens]” and “wherein the TF is exposed.” The Examiner previously indicated that these amendments would obviate the outstanding rejections. See Examiner’s Interview Summary mailed October 28, 2009. Applicants respectfully reiterate that these amendments merely emphasize features already present in the prior version of the claims.

Applicants respectfully request withdrawal of these rejections, reconsideration of this application and the timely allowance of the pending claims.


Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 25, 2010

By:



Laurence A. Shumway, Ph.D.
Reg. No. 61,169
617.452.1689